Preemptive valganciclovir for cytomegalovirus infection in hematological patients.
D
D
Focosi
E
E
Benedetti
F
F
Maggi
F
F
Papineschi
S
S
Galimberti
L
L
Ceccherini-Nelli
M
M
Petrini
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage*; D015331:Cohort Studies; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016896:Treatment Outcome; D000077562:Valganciclovir; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy*; D014775:Virus Activation
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir